#Japan #Tokyo #Medical Data #Callisto DataHub #AI Cancer Data

Callisto Celebrates Two Years by Offering Free Cancer Data Sets

Callisto Inc., based in Shinjuku, Tokyo, is commemorating the second anniversary of its medical imaging data platform, Callisto DataHub, by generously distributing free data sets to the medical research community. This initiative includes 50 cases each of X-ray data for suspected lung cancer and MRI data for prostate cancer, all compiled with expert annotations. Importantly, these data sets are sourced from Japanese medical facilities and come with reports, making them suitable for commercial use.

Overview of Callisto DataHub

Callisto DataHub specializes in providing anonymized, processed radiation, pathology images, clinical information, and molecular data collected from Japanese medical institutions. As a reliable source, it has already become a valuable resource for over 15 medical AI companies, manufacturers, and academic institutions across the United States, Europe, Korea, and Japan. Among what Callisto offers, the datasets are of high relevance for research and development in drug approval processes and marketing, especially when targeting Asian populations.

Features of the Offered Datasets

1. Japanese Data: Collectively sourced from medical facilities in Japan, making them ideal for local studies.
2. Anonymized Data: Designed with ethical and legal considerations in mind, ensuring conformity to all necessary regulations.
3. Curated Cases: The datasets comprise only suitable cases, as those with severe noise or complications have been filtered out, ensuring researchers can focus on relevant data.
4. Standardized Information: All included information—from imaging to clinical details—has been standardized to minimize the burdens of preprocessing and verification.
5. Annotated Formats: Expert annotations are available as needed, negating the requirement for separate annotation efforts.
6. Quick Availability: Callisto DataHub routinely provides these datasets within about a month, which significantly reduces the preparation time for research projects.

Types of Data Offered

The types of images included in the datasets comprise:

• - Radiology Images: X-ray showing conditions like lung nodules, mammograms for breast cancer detection, CT scans for various applications, and MRIs targeting brain tumors and breast cancer.
• - Pathology Images: Whole Slide Images (WSI) identifying various cancers.
• - Ultrasound Images: Including echocardiograms and obstetric scans.

Use Cases for Callisto DataHub Datasets

• - AI Research and Development: Useful in areas like imaging diagnosis, prognostic predictions, and biomarker discoveries.
• - Clinical Studies: Foundational for clinical trial designs and evaluations of drug efficacy and toxicity.

Building an Ecosystem of Collaboration

Callisto DataHub is a linchpin in a collaborative ecosystem involving hospitals and clinics, which supply anonymized medical images and clinical information. Callisto acts as the curator that selects, annotates, and standardizes this crucial data, facilitating its easier use in both AI research and clinical studies. Various stakeholders—including AI corporations, pharmaceutical companies, and medical device creators—can purchase these datasets to advance their own research. Callisto can also provide consultancy for additional AI development if needed.

Limited Time Offer: Free Datasets

As part of the celebration, Callisto is providing these crucial datasets for free. Interested parties can access the X-ray dataset for suspected lung cancer, which includes lesion bounding boxes, and the prostate cancer MRI dataset complete with lesion segmentation. Moreover, the company also announces the ongoing availability of a lung cancer CT dataset featuring 152 cases, professionally annotated by radiology experts, making it another excellent resource for commercial use.

To partake in this offer, individuals can navigate to the detailed pages of the datasets, add the desired dataset to the "Inquiry Cart," and agree to the usage terms before contacting Callisto for access.

With these generous provisions, Callisto not only enhances AI development and clinical research but also paves the way for meaningful discoveries in cancer diagnostics and treatment.

About Callisto Inc.

Founded on June 27, 2022, Callisto Inc. operates out of Shinjuku, Tokyo, specializing in platforms that underpin AI in medical and drug development. Under the leadership of CEO Chun-hee Han, the company continues to innovate in collaborations and research support for advancements in medical technology.

For inquiries about data provision, dataset purchases, or services related to AI and drug research, please contact via email: [email protected].

Explore further at Callisto's Official Site.